Navigation Links
Etirinotecan Pegol (NKTR-102) Passes Interim Efficacy Analysis for BEACON Pivotal Phase 3 Clinical Study in Patients with Metastatic Breast Cancer
Date:1/14/2014

ctedly fail at any time; (v) patents may not issue from our patent applications for etirinotecan pegol, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required; and (vi) the outcome of any existing or future intellectual property or other litigation related to our proprietary drug candidates. Other important risks and uncertainties are detailed in our reports and other filings with the Securities and Exchange Commission ("SEC"), including without limitation, those risks and uncertainties set forth in our quarterly report on Form 10-Q for the quarter ended September 30, 2013, filed with the SEC on November 7, 2013. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.Nektar Investor and Media Inquiries: Jennifer Ruddock/Nektar Therapeutics

(415) 482-5585Susan Noonan/SA Noonan Communications, LLC

(212) 966-3650Nektar Media Inquiries:  Brianne Cannon(415) 512-0770(1) Awada et al, Lancet Oncology 2013 Nov;14 (12):1216-25.

(2) American Cancer Society, 2007 Global Cancer Facts and Figures Report.

(3) American Cancer Society, 2009 Global Cancer Facts and Figures Report.

(4) Moreno-Aspitia and Perez, Mayo Clin Proc. 2009; 84(6):533-545


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
2. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
3. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
4. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
5. CAS REGISTRY(SM) surpasses 75 million small molecules
6. WuXi Manufacturing Facility Passes FDA Inspection
7. Tecfideras Patient Share at Three Months Postlaunch Surpasses That for Aubagio and Gilenya At the Same Stage of Their Launches
8. Emotivs Brainwear Technology To Track Cognitive Health Surpasses $1M Kickstarter Stretch Goal
9. The Leukemia & Lymphoma Society Co-Pay Assistance Fund Surpasses $200 Million
10. French Man with SynCardia Total Artificial Heart Surpasses Two Years of Support
11. NABPs .PHARMACY Proposal Passes Initial ICANN Evaluation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Most osteoporosis patients want a choice ... online survey* sponsored by Mission Pharmacal Company. The survey, ... Foundation online support community, revealed that 74 percent of ... in a form other than a pill or a ...
(Date:1/15/2014)... (the "Company") (NASDAQ: CLSN ) today announced ... purchase an aggregate of approximately $15 million of the ... led by a dedicated health care fund. ... investors pursuant to which the Company agreed to sell ...
(Date:1/15/2014)... 15, 2014  Manufacturers, suppliers and distributors of innovative ... protect their most important business assets, intellectual property ... Because of the highly-competitive nature of ... of the most litigious industry sectors of cases ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
... Md., June 01, 2007 /PRNewswire-FirstCall/ --,EntreMed, Inc. ... the treatment of cancer and inflammatory diseases,announced ... Aurora,kinase - angiogenesis inhibitor, ENMD-981693. The data ... EntreMed,scientists at the 2nd Protein Kinases in ...
... Calif., June 01, 2007,/PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. ... ongoing clinical,studies of SNS-595 and SNS-032 at the ... held June 7-10, 2007 in Vienna,Austria. , Presentations ... 1 clinical trial of SNS-595 in acute leukemias, ...
Cached Medicine Technology:EntreMed's Aurora Kinase Inhibitor Induces Tumor Regression in,Preclinical Models 2EntreMed's Aurora Kinase Inhibitor Induces Tumor Regression in,Preclinical Models 3Sunesis Pharmaceuticals to Present Data at the 12th Congress of the,European Hematology Association 2Sunesis Pharmaceuticals to Present Data at the 12th Congress of the,European Hematology Association 3
(Date:7/11/2014)... 11, 2014 Shoulder instability is a ... return to play has not been regularly determined following ... Society for Sports Medicine’s ( AOSSM ) Annual Meeting ... approximately 90 percent no matter what the stabilization procedure ... rate of return to play following shoulder stabilization surgery. ...
(Date:7/11/2014)... occur more than 200,000 times a year, but the ... may determine how long you stay in the game, ... Meeting of the American Orthopaedic Society of Sports Medicine ... in a young athletic population, allografts (tissue harvested from ... harvested from the patient)," said Craig R. Bottoni, MD, ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Woodland Hills ... founder of the Anacapa Dental Art Institute in Woodland Hills ... Biocare World Symposium in Marina Del Rey, Calif. , ... master class on the permanent teeth in one day dental ... teeth in one day was developed 15 years ago, Dr. ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 The World Cup ... according to recent reports , many star soccer players left ... in the media to American football when it comes to ... risk is always there. While none of the soccer superstars ... possibility remains. Beverly Hills spine surgeon Dr. Gravori reveals some ...
(Date:7/11/2014)... 2014 On Tuesday, July 9, Eric ... VA office joined CBS affiliate WUSA’s Andrea Roane ... the audience about the number of ways Shady Grove ... motherhood possible for women after they undergo cancer ... patients in the developing field known as oncofertility which ...
Breaking Medicine News(10 mins):Health News:Stabilizing Shoulder Surgery Helps NFL Players Return to the Game 2Health News:ACL reconstructions may last longer with autografts 2Health News:Woodland Hills Dental Expert Speaking at Nobel Biocare World Symposium in One Week 2Health News:Woodland Hills Dental Expert Speaking at Nobel Biocare World Symposium in One Week 3Health News:Woodland Hills Dental Expert Speaking at Nobel Biocare World Symposium in One Week 4Health News:Woodland Hills Dental Expert Speaking at Nobel Biocare World Symposium in One Week 5Health News:As World Cup Comes to an End, Injuries are Star of the Show 2Health News:As World Cup Comes to an End, Injuries are Star of the Show 3Health News:Baby After Cancer Is a Reality as Shady Grove Fertility Provides Successful Treatment for Cancer Survivors 2Health News:Baby After Cancer Is a Reality as Shady Grove Fertility Provides Successful Treatment for Cancer Survivors 3Health News:Baby After Cancer Is a Reality as Shady Grove Fertility Provides Successful Treatment for Cancer Survivors 4
... The University of Houston (UH) will soon open its doors ... a new joint venture between the UH Graduate College of ... Cancer Center Division of Cancer Prevention and Population Sciences. CHEER ... the newly opened center at UH GCSW. CHEER ...
... blood vitamin D levels, there,s uncertainty about where the ... threshold amount has become controversial as several scientific societies ... University of Washington researchers conducted an observational study. They ... circulating in the blood to lower the risk of ...
... , TUESDAY, May 1 (HealthDay News) -- Children with ... hospitalized than children without arthritis, a new study says. ... higher infection risk among kids with arthritis, other arthritis ... inhibitors -- were not. Researchers analyzed Medicaid ...
... can have as much effect on the teens, substance ... "Among friendship groups with ,good parents, there,s a ... aware of your whereabouts, and your friends, parents are ... you are less likely to use substances," said Michael ...
... announced today the inaugural class of its Presidential ... early career researchers with financial support to attend ... exclusive networking and mentoring opportunities with AcademyHealth leadership ... "The presidential scholarships are an opportunity for ...
... 1, 2012 Scientists at Joslin Diabetes Center have identified ... rapamycin) protein kinase, a critical regulator of cell growth which ... finding not only illuminates the physiology of aging but could ... conditions, such as cancer, type 2 diabetes, and neurodegeneration. ...
Cached Medicine News:Health News:University of Houston Graduate College of Social Work announces partnership with MD Anderson 2Health News:Researchers determine vitamin D blood level for reducing major medical risks in older adults 2Health News:Arthritis in Children Linked to Infections 2Health News:It takes a village to keep teens substance free 2Health News:First recipients of AcademyHealth's Presidential Scholarship announced 2Health News:Joslin scientists identify important mechanism that affects the aging process 2Health News:Joslin scientists identify important mechanism that affects the aging process 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: